IGF-1 receptor activity in the Golgi of migratory cancer cells depends on adhesion-dependent phosphorylation of Tyr1250 and Tyr1251 by Rieger, Leonie et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title IGF-1 receptor activity in the Golgi of migratory cancer cells depends on
adhesion-dependent phosphorylation of Tyr1250 and Tyr1251
Author(s) Rieger, Leonie; O’Shea, Sandra; Godsmark, Grant; Stanicka, Joanna;
Kelly, Geraldine; O’Connor, Rosemary
Publication date 2020-05-26
Original citation Rieger, L., O’Shea, S., Godsmark, G., Stanicka, J., Kelly, G. and
O’Connor, R. (2020) ‘IGF-1 receptor activity in the Golgi of migratory
cancer cells depends on adhesion-dependent phosphorylation of Tyr1250
and Tyr1251’, Science Signaling, 13(633), eaba3176. doi:
10.1126/scisignal.aba3176
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://dx.doi.org/10.1126/scisignal.aba3176
Access to the full text of the published version may require a
subscription.
Rights © 2020, the Authors. Published under license by the American
Association for the Advancement of Science. This is the author’s
version of the work. It is posted here by permission of the AAAS for
personal use, not for redistribution. The definitive version was
published in Science Signaling 13(633) on 26 May 2020, doi:
10.1126/scisignal.aba3176
Item downloaded
from
http://hdl.handle.net/10468/10125
Downloaded on 2020-06-06T01:30:34Z
  
IGF-1 receptor activity in the Golgi of migratory cancer cells depends on 
adhesion-dependent phosphorylation of tyrosines 1250 and 1251 
 
Leonie Rieger1, Sandra O’Shea1, Grant Godsmark1, Joanna Stanicka1, Geraldine Kelly1 and 
Rosemary O’Connor1* 
 
1 Cell Biology Laboratory, School of Biochemistry and Cell Biology, BioSciences Institute, 
University College Cork, Cork, Ireland 
 
*Corresponding author. Email: r.oconnor@ucc.ie  
 
 
Abstract  
Although insulin-like growth factor (IGF-1) signaling promotes tumor growth and cancer 
progression, therapies that target the IGF-1 receptor (IGF-1R) have shown poor clinical efficacy. 
To addresses IGF-1R activity in cancer cells and how it differs from that of the closely related 
insulin receptor (IR), we focused on two tyrosines in the IGF-1R C-terminal tail that are not 
present in the IR and are essential for IGF-1–mediated cancer cell survival, migration, and 
tumorigenic growth. We found that Tyr1250 and Tyr1251 (Tyr1250/1251) were autophosphorylated in 
a cell adhesion–dependent manner. To investigate the consequences of this phosphorylation, we 
generated phosphomimetic Y1250E/Y1251E (EE) and non-phosphorylatable Y1250/Y1251F 
(FF) mutant forms of IGF-1R. Although fully competent in kinase activity and signaling, the EE 
mutant was more rapidly internalized and degraded than either the wild-type or FF receptor. 
IGF-1 promoted accumulation of wild-type and EE IGF-1R within the Golgi apparatus, whereas 
the FF mutant remained at the plasma membrane. Golgi-associated IGF-1R signaling was a 
feature of migratory cancer cells, and Golgi disruption impaired IGF-1–induced signaling and 
cell migration. Upon the formation of new cell adhesions, IGF-1R transiently re-localized to the 
plasma membrane from the Golgi. Thus, phosphorylation at Tyr1250/1251 promoted IGF-1R 
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translocation to and signaling from the Golgi to support an aggressive cancer phenotype. This 
could contribute to the poor clinical efficacy of antibodies that target IGF-1R on the cell surface 
and also distinguish IGF-1R from IR signaling.  
 
Introduction 
The receptor-like tyrosine kinase (RTK) insulin-like growth factor–1 receptor (IGF-1R) and its 
ligands (IGF-1 and IGF-2) are widely present throughout different cell and tissue types and play 
essential roles in cell, organ, and organismal growth (1, 2). The IGF system is also linked to 
cancer risk, tumorigenesis, tumor growth and survival, and to promoting cell migration in both 
normal and transformed cells (3-6). Many pre-clinical studies have shown a clear effect of IGF-
1R suppression or inhibition on limiting tumorigenesis, tumor growth and metastatic potential (3, 
4, 6). However, this has not been replicated in large-scale clinical trials, wherein IGF-1R 
blocking antibodies and kinase inhibitors show an overall poor efficacy (3, 4). There are no 
predictive biomarkers for IGF-1R activity, and there is limited understanding of the cellular 
signaling events that promote resistance to or evasion of IGF-1R inhibitors. 
Although IGF-1 signaling in cancer cells has been extensively studied, it is still poorly 
understood how IGF-1R expression, abundance, and signaling output are influenced by 
oncogenic and adhesion signals in different cancers. Amounts of cell surface IGF-1R may not 
predict responses to ligand stimulation in terms of downstream signaling output, and this is 
apparently influenced by the cancer cell phenotype, such as migratory versus non migratory (7). 
We and others previously demonstrated that adhesion signals enhance IGF-1R activation and 
signaling, and that integrin-mediated signaling is essential for IGF-1 to promote cancer cell 
proliferation and migration (reviewed in (8)). Moreover, the association of IGF-1R with E-
 3 
cadherin and with discoidin domain receptors (DDRs), which are receptor tyrosine kinases 
activated by binding to collagen, can control receptor stability and signaling output (9-11). 
Cooperation between integrin β1 and IGF-1R signaling involves an adhesion-dependent 
signaling complex composed of scaffolding proteins, focal adhesion kinase (FAK), and 
phosphatases that ultimately leads to activation of mitogen-activated protein kinase (MAPK) 
pathways (12-15). Mutation of two tyrosines (Tyr1250 and Tyr1251) in the C-terminal tail of IGF-
1R is sufficient to abrogate the receptor's function in facilitating cellular transformation, cell 
survival, and migration (16-18). These tyrosine residues were also found to be essential for 
integrating IGF-1R and adhesion signaling (14). However, these tyrosines are not present in the 
human insulin receptor (IR), which has an almost identical kinase domain to the IGF-1R but 
shares less than 50% homology with the C-terminal tail. We previously hypothesized that the 
function of these tyrosines may distinguish IGF-1R and IR actions in cell growth and cancer (14, 
17, 19). However, despite the clear loss of IGF-1R function observed upon mutation of Tyr1250 
and Tyr1251 (Tyr1250/1251) to phenylanines (Y1250F/Y1251F), and in silico predictions for 
phosphorylation in cells (14, 16-21), evidence for actual phosphorylation in vivo has remained 
elusive, as has knowledge of how this phospho-site functions. This has hindered efforts to 
understand how these IGF-1R tyrosines facilitate tumourigenesis or how this site may distinguish 
IGF-1R and IR signaling.  
In this study, using mass spectroscopy and phospho-specific antibodies, we established 
that the IGF-1R was basally autophosphorylated on Tyr1250/1251 in cells, and this depended on 
IGF-1 and adhesion signaling. We determined the functions of Tyr1250/1251 phosphorylation by 
using a phosphomimetic mutant (Y1250E/Y1251E, referred to as the EE mutant) form of IGF-
1R, which was more rapidly internalized and less stable than the wild-type IGF-1R or the 
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Y1250F/Y1251F (FF) mutant. Upon IGF-1 stimulation, both the wild-type and the EE mutant 
IGF-1R rapidly accumulated within the Golgi apparatus, whereas the FF mutant was retained on 
the plasma membrane. IGF-1R localization in the Golgi-apparatus was associated with migratory 
potential, and an intact Golgi apparatus was required for IGF-1R signaling in migrating cells. 
Overall, the data indicate that Tyr1250/1251 phosphorylation drives translocation of IGF-1R to the 
Golgi, where it contributes to a migratory phenotype. These results distinguish IGF-1R and IR 
function, and may also explain the inefficacy of targeting cell surface IGF-1R with monoclonal 
antibodies in several cancers.  
 
Results  
Phosphorylation of IGF-1R on Tyr1250 and Tyr1251 occurs in cells 
First, to address the question whether the Tyr1250/1251 site becomes phosphorylated in cells, we 
used mass spectroscopy and phosphopeptide analysis of IGF-1R immunoprecipitated from 
mouse embryonic fibroblasts derived from IGF-1R knockout mice (R- cells) transiently 
expressing the receptor and either serum-starved or stimulated with IGF-1. The isolation of IGF-
1R phosphopeptides including Tyr1250/1251 was less efficient than isolation of other 
phosphopeptides from the receptor, which we attributed to the fact that these tyrosines reside 
within a sequence (SFYYS) that also includes phosphorylated serines (20, 22), and would thus 
be highly charged and difficult to capture. Following peptide extraction and mass spectrometry 
analysis, a series of phosphopeptides was identified (ion score >19) containing tyrosines that are 
known to be phosphorylated in response to IGF-1, including Tyr950 and the kinase activation site 
tyrosines Tyr1131, Tyr1135, and Tyr1136 (Fig. 1A). In addition, phosphopeptides were captured 
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from both serum-starved and IGF-1–stimulated cells with phosphorylation on the Tyr1250 site, 
with a higher score indicating IGF-1–induced phosphorylation (Fig. 1A).  
We next employed an antibody specific for the phosphorylated Tyr1250/1251 site to further 
assess Tyr1250/1251 phosphorylation over time in response to either serum starvation or IGF-1. In 
phosphopeptide arrays, an antibody known to recognize phosphorylated Tyr1250 also detected 
peptides containing either the single phosphorylated site or the doubly phosphorylated site (fig. 
S1, A and B), and we therefore concluded that this antibody reacts with the Tyr1250/1251 
phosphosite. We next compared the profile of IGF-1–stimulated phosphorylation of the 
Tyr1250/1251 phosphosite with the IGF-1R autophosphorylation sites Tyr950, Tyr1131, and 
Tyr1135/1136. This analysis demonstrated that basal amounts of Tyr950, Tyr1130, and Tyr 1135/1136 
phosphorylation were low and then rapidly induced by IGF-1 at 1-5 min. In contrast, basal 
phosphorylation of Tyr1250/1251 was evident in serum-starved cells, and IGF-1–induced 
phosphorylation at this site accumulated more slowly than it did at the other sites (Fig. 1B). This 
result is consistent with the mass spectrometry analysis indicating phosphorylation in serum-
starved cells (Fig. 1A).  
Although IGF-1 displays greater affinity for IGF-1R than for IR, and insulin displays 
greater affinity for IR than for IGF-1R, each can activate the other receptor when the ligand 
concentration is high. Therefore, we investigated whether Tyr1250/1251 phosphorylation was 
influenced by ligand concentration in serum-starved R- cells expressing wild-type (WT) IGF-1R 
stimulated with either 1, 10, 50, or 100 ng/ml IGF-1. From this we observed that Tyr1250/1251 
phosphorylation was induced in a dose-responsive manner with highest amounts of 
phosphorylation reached at 50 ng/mL (Fig. 1C). Insulin did not induce phosphorylation on 
Tyr1250/1251 even at 100 ng/mL, although it modestly induced phosphorylation of the kinase AKT, 
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which is known to mediate activation of the mTOR pathway, metabolism, growth and survival, 
but not phosphorylation of extracellular signal–regulated kinase (ERK), known to promote 
mitogenic, differentiation and migratory signals, at this concentration (Fig. 1D). IGF-2 also 
induced Tyr1250/1251 phosphorylation (Fig. 1D). We also observed phosphorylation on Tyr1250/1251 
of endogenous IGF-1R in the cancer cell lines MDA-MB-231, Cal-51, HS-578T, and DU-145 
(Fig. 1E). Again, Tyr1250/1251 phosphorylation was observed in serum-starved cells, and this 
increased upon IGF-1 stimulation (Fig. 1E).  Together, these data demonstrate that Tyr1250/1251 
phosphorylation was present in cells at low basal amounts and was induced by IGF-1 in a 
concentration- and time-dependent manner. 
 
Adhesion signals and IGF-1R kinase activity are required for Tyr1250/1251 phosphorylation  
Because IGF-1 enhanced phosphorylation of IGR-1R at Tyr1250/1251 and this phosphorylation 
event had not previously been demonstrated in cells, we next investigated whether it was a bona 
fide autophosphorylation site in IGF-1R. The first approach was to determine whether Tyr1250/1251 
phosphorylation could be induced in the presence of an inhibitor of IGF-1R kinase activity. In 
serum-starved cells Tyr1250/1251 phosphorylation was not affected by the IGF-1R kinase inhibitor 
BMS754807 (Fig. 2A). However, IGF-1–mediated enhancement of Tyr1250/1251 phosphorylation 
was abolished by the kinase inhibitor, indicating that IGF-1–induced phosphorylation of 
Tyr1250/1251 was likely a result of autophosphorylation. To further test autophosphorylation, we 
assessed autophosphorylation of WT IGF-1R and a kinase-inactive form of IGF-1R (K1003R, an 
ATP-binding site mutant, referred to henceforth as KR), in the absence or presence of 
exogenously added ATP to stimulate kinase activity. Although phosphorylation on Tyr1250/1251 
was detectable on both the WT and KR receptors, this was increased by exogenous ATP on the 
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WT but not on the KR receptor (Fig. 2B). This indicates that IGF-1R kinase activity was 
required for phosphorylation on Tyr1250/1251. The observation that phosphorylation was evident 
with the KR mutant and with WT IGF-1R in serum-starved cells also suggests that other cellular 
kinases may phosphorylate Tyr1250/1251. 
Previous studies have shown that the Tyr1250/1251 site is required for cooperative IGF-1R 
and adhesion signaling (14) and that IGF-1R kinase activity is influenced by adhesion signaling 
and adhesion-associated kinases (23, 24). Therefore, we asked whether adhesion-activated 
kinases (FER, FAK and Src) contributed to Tyr1250/1251 phosphorylation. To test this we used 
Cal-51 breast cancer cells, in which IGF-1 and adhesion signaling are active (10, 25), and 
measured IGF-1–induced phosphorylation at the Tyr1250/1251 site and at the Tyr1135/1136 site, which 
is required for full kinase activation, in the presence of either the IGF-1R kinase inhibitor BMS-
754807, a FER kinase inhibitor (AP-26113), a FAK kinase inhibitor (PF-573228), or a Src 
kinase inhibitor (PP2) (Fig. 2C). We observed that IGF-1–induced phosphorylation on both sites 
was decreased by BMS, AP-26113, and PF-573228 but not by PP2 (Fig. 2C). Thus, inhibition of 
IGF-1R, FER or FAK kinase activity suppressed IGF-1R autophosphorylation and full kinase 
activation. A requirement for adhesion signaling in full IGF-1R autophosphorylation was also 
observed with cells that were detached from the substratum. IGF-1–stimulated phosphorylation 
of the Tyr950, Tyr1131, Tyr1135/1136, and Tyr1250/1251 sites was reduced by detachment of R- cells 
expressing WT IGF-1R, as well as by detachment of Cal-51 and DU-145 cancer cells (Fig. 2, D 
and E). IGF-1–induced activation of AKT and ERK was also reduced in detached cells compared 
to adherent cells (Fig. 2, D and E). We conclude that both IGF-1R and adhesion signaling were 
essential for maximal phosphorylation of the IGF-1R on Tyr1250/1251 and that cell adhesion 
enhanced overall IGF-1R autophosphorylation and activation.  
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A Tyr1250/1251 phosphomimetic mutant IGF-1R is fully active but rapidly turned over 
The next question to be addressed was how phosphorylation on the Tyr1250/1251 site contributed to 
IGF-1R function and signaling. To address this, we generated a phosphomimetic for this site, a 
mutant IGF-1R with tyrosines Tyr1250/1251 substituted by negatively charged glutamic acids, the 
EE mutant. When transiently transfected into either R- cells or three different cancer cell lines 
(MCF-7, MDA-MB-231, DU-145) in which the IGF-1R was knocked out by CRISPR 
technology, the EE mutant was consistently expressed at significantly lower levels than either the 
WT or FF IGF-1R (Fig. 3A). A similar pattern of lower receptor protein abundance was 
observed in R- cells stably expressing EE IGF-1R (fig. S2A), although mRNA expression across 
the transfected WT, FF, and EE constructs was similar (fig. S2B). Single mutation of either 
Tyr1250 or Tyr1251 to glutamic acid was also sufficient to impair receptor protein abundance 
compared to WT IGF-1R (fig. S2C).  
Although present in lower amounts in cells, the EE mutant was observed to be functional 
and to mediate IGF-1–stimulated kinase activation and downstream signaling. Cells expressing 
either WT or EE IGF-1R exhibited similar IGF-1–stimulated AKT and ERK activation (Fig. 3B). 
The FF mutant exhibited lower IGF-1R and ERK activity than WT IGF-1R (Fig. 3B), which is 
consistent with previous studies (19). Transient overexpression of WT, FF, or EE IGF-1R in 
MDA-MB-231 IGF-1R knockout cells (MDA-KO) also demonstrated that the activation of EE 
IGF-1R was comparable to that of WT IGF-1R, whereas it was higher than that of FF IGF-1R 
(Fig. 3C). In vitro kinase assays were used to compare the IGF-1R kinase activity of the EE 
mutant with WT IGF-1R and the FF mutant. In vitro EE IGF-1R kinase activity was similar to 
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that of WT IGF-1R, whereas FF IGF-1R kinase activity was lower than that of WT IGF-1R (Fig. 
3D), as also previously reported (17).  
The lower cellular abundance of the EE mutant compared to WT IGF-1R and the FF 
mutant suggested that Tyr1250/1251 phosphorylation influenced the translation or stability of the 
IGF-1R protein. We first ruled out the possibility that low EE protein was due to impaired 
protein synthesis by using cycloheximide (CHX) to transiently suppress protein synthesis, and 
then assessing the amount of newly synthesized protein over time. In these experiments it was 
clear that similar amounts of WT IGF-1R and mutant IGF-1Rs were restored following CHX 
exposure (Fig. 4A), thereby indicating similar amounts of synthesis. We next tested whether 
inhibition of proteasomal or lysosomal activity could restore EE IGF-1R protein in cells. The 
IGF-1R protein is synthesized as a pro-receptor that is processed to yield an extracellular α chain 
and intracellular β chain. The functional receptor is a homo-dimer of two α chains and two β 
chains that are joined by disulphide bonds.  Inhibition of proteasomal activity with MG-132 for 
6hr restored the EE β-chain to protein abundances that were similar to those of WT IGF-1R and 
FF IGF-1R in control cells, and the abundance of the pro form of the receptor was also recovered 
(Fig. 4B). Lysosomal inhibition with E64D+Leupeptin or Chloroquine did not affect EE protein 
abundance (Fig. 4C), indicating that the EE mutant was not more susceptible to lysosomal 
degradation than WT.   
We also investigated whether stimulation of R- cells with high or low concentrations of 
IGF-1 influenced the degradation of the EE and WT IGF-1R compared to the FF IGF-1R. This 
demonstrated that IGF-1 stimulation at either high or low IGF-1 concentrations resulted in a 
similar reduction in amounts of the WT and EE receptors at 6 and 12 hours, whereas the 
abundance of the FF receptor was not significantly reduced after 6 hours and was comparable to 
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its abundance in unstimulated cells (Fig. 4D). Thus, the FF mutant was protected from 
degradation. Together, these results demonstrate that the IGF-1R EE mutant was kinase-active 
and responsive to IGF-1 but was less stable than WT IGF-1R. The data suggest that Tyr1250/1251 
phosphorylation accelerated IGF-1R protein turnover. 
 
Tyr1250/1251 phosphorylation promotes IGF-1R translocation to the Golgi apparatus 
The IGF-1R EE mutant was highly active in signaling even with low amounts of protein in the 
cells, so we next investigated its subcellular location and compared IGF-1–stimulated 
internalization and trafficking of the EE receptor with that of the WT and FF receptors. 
Although, as expected, the WT receptor was mainly located on the cell membrane in serum-
deprived cells, we observed that a pool of IGF-1R was located at the perinuclear region in these 
cells (Fig. 5A). In IGF-1–stimulated cells, both WT and EE receptors were visible in large 
intracellular vesicles. Over time these vesicles appeared to accumulate at the perinuclear region 
and were less evident at the plasma membrane (Fig. 5A). These IGF-1R–containing vesicles 
were overall less evident in cells expressing the FF mutant receptor, in which the receptor was 
predominantly located at the plasma membrane (Fig. 5A). The relative translocation patterns of 
IGF-1R WT and EE in cells were illustrated by showing the intensity in IGF-1R fluorescence 
signal along a line that was drawn diagonally from cell membrane to cell membrane through the 
nucleus (Fig. 5B). Without IGF-1, cells expressing the EE mutant exhibited a clear peak in IGF-
1R fluorescence signal close to the nucleus. This peak was less prominent in cells expressing WT 
IGF-1R and was not visible in cells expressing FF IGF-1R. Over time cells expressing either WT 
or EE displayed a shift in IGF-1R fluorescence signal towards the nucleus and a reduction in 
signal intensity near the plasma membrane.  
 11 
Receptor internalization was also assessed using in-cell Western assays to quantify the 
ratio of IGF-1R present at the plasma membrane relative to total amount of the receptor in cells 
that were stimulated with IGF-1. Whereas the amounts of the receptor at the cell surface declined 
in response to IGF-1 in cells expressing either the WT or EE receptors, the cell surface amounts 
of FF receptors were not altered (Fig. 5C). To test whether WT and EE IGF-1Rs were being 
actively internalized into vesicles, we used an antibody that recognizes the α chain of IGF-1R 
(IRα) and is known to induce IGF-1R internalization (3). R- cells expressing the WT, FF, or EE 
IGF-1R were serum-starved for 4 hr and cultured with the IRα antibody for 30 min either at 37˚C 
(Fig. 5D) or on ice (fig. S3A) followed by staining with an antibody detecting the β chain of 
IGF-1R and immunofluorescence analysis for co-localization (Fig. 5D, fig. S3B). The IRα-
specific antibody was internalized in vesicles after 30 min in cells expressing the WT or EE IGF-
1R, whereas co-localization of IRα with the β-chain was observed at the plasma membrane in 
cells expressing the FF mutant. We conclude that activated WT and EE IGF-1Rs were rapidly 
internalized into intracellular vesicles that accumulated at the perinuclear region over time. The 
observation that the FF mutant neither accumulated within vesicles nor underwent post-
endocytotic trafficking suggests that phosphorylation on Tyr1250/1251 was required for 
internalization and accumulation of IGF-1R at the perinuclear region. 
Post-endocytic trafficking of surface receptors and proteins to the Golgi apparatus has 
been described as retrograde trafficking and a process that may be important for cell signaling 
(26, 27). We therefore further investigated IGF-1R co-localization with the Golgi marker GM130 
in cells expressing WT, FF, or EE IGF-1R. Over time, the WT and EE IGF-1Rs co-localized 
with GM130 at the cis-Golgi compartment (Fig. 6A). Co-localization of IGF-1R with a 
biotinylated form of the lectin VVA, which labels N-acetylgalactosamine and is a marker for 
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both trans- and cis-Golgi, was also evident (Fig. 6B). The EE mutant was also observed at the 
Golgi apparatus in serum-starved cells, suggesting that phosphorylation on Tyr1250/1251 was 
sufficient for translocation to the Golgi. To further test whether WT and EE IGF-1Rs were 
present in the Golgi apparatus, we used Brefeldin A (BFA) to induce cis-Golgi fragmentation 
(28) in R- cells expressing the WT, EE, or FF receptor. Fragmentation of the cis-Golgi resulted 
in lower amounts of WT and EE receptors (Fig. 6C), whereas BFA did not affect the FF mutant 
receptor. Taken together, these results indicate that IGF-1-induced internalization and 
accumulation of the IGF-1R in the Golgi apparatus required phosphorylation on Tyr1250/1251. 
 
Tyr1250/1251 phosphorylation and adhesion signals promote IGF-1R presence in and signaling 
from the Golgi  
The Tyr1250/1251 site is required to support a transformed phenotype, cancer cell survival, cell 
migration, tumor growth, and metastasis in vivo (3, 18, 29). Because Golgi-derived signaling is 
implicated in cell migration (30), we hypothesized that Tyr1250/1251 phosphorylation and IGF-1R 
Golgi localization may be a feature of migratory cancer cells. To test this, we compared IGF-1R 
localization in non-migratory MCF-7 cancer cells to that in migratory MDA-MB-231 and HS-
578T cells, both of which also exhibited relatively high IGF-1R Tyr1250/1251 phosphorylation (Fig. 
1E). Whereas the IGF-1R was evident at sites of focal adhesion (FA) in MCF-7 cells, it was also 
clearly located within the Golgi apparatus in MDA-MB-231 and HS-578T cells (Fig. 7A). IGF-
1R abundance was reduced by the Golgi disruptor BFA in MDA-MB-231 and HS-578T cells, 
but not in MCF-7 cells (Fig. 7B). Furthermore, although disruption of the Golgi with BFA did 
not alter the distribution of the IGF-1R at the plasma membrane in MCF-7 cells, BFA caused 
dispersal of the IGF-1R from the Golgi apparatus in MDA-MB-231 and HS-578T cells (Fig. 7C). 
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In these cells IGF-1R staining remained visible at the leading edge within lamellipodia. IGF-1–
induced phosphorylation on Tyr1250/1251 was detectable in both MCF-7 and HS-578T cells, but 
basal amounts of SHC [Src homology 2 (SH2) domain–containing] phosphorylation and IGF-1–
induced SHC phosphorylation were impaired by BFA in HS-578T cells, but not in MCF-7 cells 
(Fig. 7D). 
Because IGF-1R was observed at the lamellipodia of cells even when the Golgi was 
disrupted (Fig. 7C) and Tyr1250/1251 phosphorylation required adhesion signaling (Fig. 2C-E), we 
next investigated whether cell adhesion controlled IGF-1R localization at the plasma membrane 
or Golgi in MCF-7 and HS-578T cells. IGF-1R location and phosphorylation on Tyr1250/1251 was 
monitored over time in response to the formation of nascent FA contacts in cells that were 
allowed to attach to fibronectin-coated plates and coverslips. Immunofluorescence showed that 
the IGF-1R was present at the plasma membrane in both cell types at 15 min after cell seeding 
(Fig. 8A). At this time phosphorylation on Tyr1250/1251 was low (Fig. 8B). In MCF-7 cells the 
IGF-1R was observed in FAs at 30 min after cell seeding, and it remained there for up to 60 min 
(Fig. 8A). In HS-578T cells, most of the IGF-1R had moved from the plasma membrane to the 
Golgi at 30 min and was exclusively Golgi-localized by 60 min (Fig. 8A). In MCF-7 cells 
phosphorylation on Tyr1250/1251 remained low over time after cell adhesion, whereas in HS-578T 
cells Tyr1250/1251 phosphorylation increased over time after adhesion (Fig. 8B). These 
observations indicate that the IGF-1R was rapidly recruited to nascent FAs in HS-578T cells and 
that IGF-1R and adhesion-dependent Tyr1250/1251 phosphorylation promoted subsequent 
translocation of the receptor to the Golgi.   
Directed migration of epithelial cells requires the formation of leading edge protrusion 
and adhesion to the extracellular matrix (ECM), which involves the formation of new FAs (30). 
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We therefore investigated whether the IGF-1R was recruited to FAs in migrating cells. At 6 hr 
after wounding a HS-578T cell monolayer, large FAs were visible at the leading edge of the 
migrating cells (Fig. 8C). In agreement with our earlier observations of IGF-1R at sites of 
adhesion in both migratory and nonmigratory cells (Fig. 7A), immunofluorescence analysis 
showed that the IGF-1R was clearly located within the protrusions of moving cells (Fig. 8C). In 
these cell cultures it was also clear that the IGF-1R was predominantly located in the Golgi 
apparatus within cells that were part of the high confluency monolayer. BFA abolished IGF-1–
stimulated HS-578T cell migration (Fig. 8D), indicating that the Golgi apparatus is essential for 
IGF-1-promoted cell migration. 
To better understand what promoted IGF-1R localization to the Golgi, we further 
assessed IGF-1R localization in MCF-7 and HS-578T cells that were cultured to either sub-
confluence, which allows for cell migration and cell-matrix contacts, or high confluence, which 
favors cell-cell adhesion. We observed that when cell-cell adherence was high in MCF-7 cells, 
the IGF-1R was located at the plasma membrane sites of cell-cell adhesion as previously 
described (9), whereas it was located at sites of focal cell adhesion in sub-confluent cultures (Fig. 
8E). In these MCF-7 cultures, basal phosphorylation on Tyr1250/1251 was present, and IGF-1–
induced phosphorylation of SHC was evident (Fig. 8F). In contrast, in sub-confluent HS-578T 
cells, the IGF-1R was located at the leading edge and in the Golgi with significant IGF-1–
induced phosphorylation of Tyr1250/1251 evident, whereas in confluent cells the IGF-1R was 
predominantly located in the Golgi (Fig. 8E), where constitutive Tyr1250/1251 phosphorylation was 
evident (Fig. 8, E and F). HS-578T cells growing under high-confluency conditions exhibited 
little IGF-1–stimulated SHC phosphorylation (Fig. 8F). However, induction of phosphorylation 
on Tyr1135/1136 and activation of AKT and ERK was present, confirming that the IGF-1R was 
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active within the Golgi in these cells. Taken together, these data indicate that phosphorylation on 
Tyr1250/1251 promoted the accumulation of IGF-1R in the Golgi. Within the Golgi, the IGF-1R 
was active and induced downstream signaling. On the other hand, cell-ECM adhesion signals 
during cell migration enhanced IGF-1–induced phosphorylation on Tyr1250/1251, resulting in the 
IGF-1R being located both in the Golgi and at the leading edge of migrating cells.  
 
Discussion  
Although IGF-1 signaling has a well-described function in facilitating tumorigenesis and 
promoting tumor growth, it is unresolved why the abundance of IGF-1R does not correlate with 
its activity in cancer cells and why IGF-1R–targeting drugs have been largely ineffective. Our 
findings here (summarized in the model in Fig. 9) explain a previously hidden activity of the 
IGF-1R in promoting an aggressive cancer phenotype and evading therapy. Adhesion-dependent 
phosphorylation of the IGF-1R on Tyr1250/1251 promoted receptor translocation from the plasma 
membrane to the Golgi, whence it elicited signaling and was available for transport to and from 
new FA sites in migrating cells. Ligand- and adhesion-stimulated Tyr1250/1251 phosphorylation 
and receptor internalization also accelerated the turnover of the receptor. 
Previous studies have reported that IGF-1R activity and signaling can be modulated by 
cell adhesion signals (reviewed in (8)) and directly by adhesion-associated kinases including 
FAK, Src, and FER (23, 24, 31-33). The presence of Tyr1250/1251 is necessary for the integration 
of IGF-1R and integrin β1 signaling mediated by their co-recruitment into a scaffolding complex 
containing RACK-1, SHC, and other mediators that stimulate MAPK signaling (12, 14). Loss of 
this interaction with mutation of the tyrosines to phenylalanine results in impaired IGF-1–
induced cell migration and tumor growth in vivo (14, 18). Our observations here, specifically 
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that the phosphomimetic EE mutant (for Tyr1250/1251 phosphorylation) was more rapidly 
internalized and trafficked from the Golgi apparatus to the leading edge of migrating cells, 
indicate that phosphorylation on this site is necessary for cooperation with adhesion signaling. 
IGF-1 also stimulates the internalization of WT IGF-1R to the Golgi, demonstrating that this is 
an intrinsic component of IGF-1R signaling when it is phosphorylated on these residues. In 
migrating cells, the removal of IGF-1R from FA points induced by phosphorylation on 
Tyr1250/1251 may facilitate the disassembly of FAs to promote the migration of cells, and may also 
explain the impaired migratory capacity of cells expressing the FF mutant, wherein the IGF-1R 
is retained at the plasma membrane.   
It is well documented that the outcome of RTK activation and signaling can vary 
depending on receptor location (34-36). Compartmentalization of RTK signaling may facilitate 
the recruitment of different effector proteins that might be dictated by a specific cell phenotype. 
Emerging evidence suggests an important role for the Golgi in oncogenic RTK signaling (37-39). 
Overexpressed or mutated forms of the RTK MET cause ligand-independent activation and 
signaling from MET,  including the phosphorylation of the RTK human epidermal growth factor 
receptor 3 (HER3, also known as ERBB3), in the Golgi (37). Similarly, mutated forms of the 
RTK KIT are retained in the Golgi where they are active and induce downstream signaling (38, 
40-42). The RTKs vascular endothelial growth factor receptor 2 (VEGFR2), fibroblast growth 
factor receptor (FGFR2) and epidermal growth factor receptor (EGFR, also called HER1 and 
ERBB1) are also reported to be located at and induce signaling from the Golgi (27, 35, 43). Our 
findings with the IGF-1R add important knowledge to the understanding of Golgi-derived RTK 
signaling because we demonstrate that trafficking of this RTK to the Golgi apparatus is promoted 
by a specific adhesion- and ligand-dependent phosphorylation on Tyr1250/1251. In migrating cells 
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the IGF-1R was located at the leading edge of nascent FAs and was subsequently rapidly 
trafficked back to the Golgi.  This suggests that a pool of IGF-1R phosphorylated at Tyr1250/1251 is 
stored in the Golgi for signaling and fast trafficking back to the membrane in migrating cells. 
Indeed, a similar trafficking route is proposed for Golgi membrane protein 1 (GOLM)–mediated 
trafficking of ligand-activated EGFR in hepatocellular carcinoma (27).  
We have not however established if the IGF-1R is a cargo protein, if it might participate 
in regulating the secretion of proteins from the Golgi, or what controls its trafficking out of the 
Golgi. Phosphorylation on Tyr1250/1251 was low when the IGF-1R was recruited to the membrane, 
which suggests that phosphatases may facilitate the dephosphorylation of Tyr1250/1251, leading to 
the release of IGF-1R from its Golgi location. Once located at points of nascent FAs, the IGF-1R 
may promote the recruitment of other interaction partners and proteins leading to the 
stabilization of FAs.  It is likely that the IGF-1R is subsequently removed from FAs following 
phosphorylation on Tyr1250/1251. An alternative possibility is that the IGF-1R traffics to the Golgi 
compartment as part of a multi-protein complex that is stored there for signaling.  
Golgi-derived oncogenic signaling may be especially active in cell migration (30). Here 
we observed that fragmentation of the Golgi impaired cell migration in the presence of IGF-1. 
This was associated with impaired SHC phosphorylation in migratory HS-578T cells but not in 
non-migratory MCF-7 cells. This is consistent with a previously described requirement for an 
intact Golgi apparatus in activating the RAS pathway and ERK signaling to establish cell 
polarity in migrating cells (30). The observation that impaired SHC phosphorylation was not 
observed in non-migratory cells suggests that different signaling outcomes can be dictated by the 
same receptor depending on its location and on the cell phenotype as previously suggested (7). 
Our data suggest that distinct cell adhesion signals have an essential function in determining 
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IGF-1R autophosphorylation and location. Mesenchymal cancer cells exhibiting high migratory 
capacity and aggressiveness are often deficient in E-cadherin, which interacts with the IGF-1R 
and may retain it at cell-cell junctions in, for example, MCF-7 cells (9). Loss of E-cadherin 
would therefore be likely to alter IGF-1R localization and potentially facilitate interactions with 
integrins.  
Activated intracellular and nuclear IGF-1R have previously been linked to an aggressive 
cancer phenotype. Intracellular IGF-1R is more abundant in malignant than in benign epithelium 
in samples from prostate cancer patients (44), and nuclear IGF-1R has been proposed to facilitate 
breast and prostate cancer (45, 46). Moreover, although abundance of the IGF-1R itself is not 
associated with survival in breast cancer patients, high amounts of IGF-1R phosphorylation are 
linked to poor outcomes (47). Our finding of Golgi-derived IGF-1R signaling offers a 
mechanistic explanation for these effects, because although the EE IGF-1R was present in lower 
amounts in cells, it retained high activity. 
In summary, phosphorylation-specific trafficking of the IGF-1R to the Golgi and the 
association of this with aggressive cancer phenotype has important consequences for IGF-1 
signaling. Phosphorylated Tyr1250/1251 could be a biomarker for identifying subsets of cancer that 
may not be targetable with antibodies targeting the receptor but may be amenable to other 
therapies that would target an IGF-1R signaling hub within the Golgi. Moreover, this 
phosphorylation site may distinguish IGF-1R and IR signaling in cells. 
 
Materials and Methods 
Cell culture, ligand stimulation, and pharmacological inhibitors  
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R- cells, MDA-MB-231 and HS578T cells were maintained in Dulbecco’s Modified Eagles 
Medium (DMEM). Cal-51 were cultured in 50/50 mix of DMEM/Hams Nutrient F12 media. 
Prostate cancer DU-145 cells were cultured in RPMI 1640. Media were supplemented with 10% 
(v/v) heat inactivated fetal bovine serum, 10 mM L-Glutamine, with 5 mg/ml 
penicillin/streptomycin added. Cells were cultured at 37 °C in a humidified atmosphere at 5% 
CO2. All cells were determined to be free of mycoplasma by  specific DNA staining and 
routinely maintained in culture for up to 6- 8 weeks for use in experiments. 
For the analysis of IGF-1 stimulation in western blotting, cells were seeded 20 hr prior to 
starvation and allowed to reach approximately 70% confluency. Cells were serum-starved for 4 
hr followed by stimulation with the indicated concentrations of IGF-1, IGF-2 or Insulin. 
Generally, R- cells transiently expressing the IGF-1R were stimulated with 10 ng/ml IGF-1 and 
cell lines with endogenous IGF-1R were stimulated with 50 ng/ml IGF-1.  
For the analysis of detached cells (suspension), cells seeded on 10 cm plates were 
cultured overnight in complete medium and the starved from serum for 4 hr in total. After 3 hr 
cells were enzymatically detached and left in suspension for 1hr. Cells were then stimulated with 
IGF-1, centrifuged at 1000 rpm for 5 minutes, washed with PBS and lysed. 
Kinase inhibitors BMS-754807 (Stratech/Selleckchem, cat# S1124-SEL;300 nM and 
1000 nM) AP26113 (Stratech/Selleckchem; cat# S7000-SEL; 500 nM), PF-573228 (Tocris 
Bioscience,cat#3239-10; 9 µM) and PP2 (Sigma/Merk; cat#529573-5mg; 35 µM) were added to 
cells for the last hour of 4 hr serum starvation.  
The proteosomal or lysosomal inhibitors MG-132 (Calbiochem, cat#474790; 10 µM, 
Leupeptin (Sigma/Merk; cat#L2884-25 mg; 2 µM), E64 (Sigma/Merk; cat#E3132-5mg; 2.6µM) 
and Chloroquine (CQ) (Cell Signalling, cat#14774; 50 µM) were added to cell cultures for 4 or 6 
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hr and the appropriate vehicle was added to controls (0 h). The Golgi disruptor Brefeldin A 
(Sigma/Merk; cat# B7651-5mg; 10 µg/ml) was added to cells in complete medium.  
 
Generation and transfection of IGF-1R mutants 
Cells were transiently transfected with pcDNA4 plasmid encoding the WT IGF-1R or Kinase 
dead (K1003R) mutant and pcDNA4 plasmid encoding IGF-1R WT, FF or EE mutants. R- cells, 
cells were seeded 24 hr prior to transfection at a density of approximately 1.0x 106 cells/10 cm 
plate. Lipofectamine 2000 (Invitrogen cat# 11668-019) diluted in OptiMem was used to transfect 
cells with relevant DNA plasmid (12-16 µg). After 24 hr cells were re-seeded for experiments at 
48 hr post transfection. 
 MDA-MB-231, MCF-7 and DU-145 cells were seeded 24 hr prior to transfection to 
approximately 70% confluency in 6-well or 10 cm plates for transfection with Lipofectamine 
2000. All cell lines were transfected with 2 µg/6 well plate and 12 µg/10 cm plate of pcDNA4 
plasmid. Cells were re-seeded in new plates at 24 hr post transfection for subsequent experiments 
IGF-1R mutants were generated using the Quick-Change Lightning SDM Kit (Agilent, 
#210518). The pcDNA4 plasmid encoding WT IGF-1R was used to generate the K1003R, 
Y1250/Y1251 to phenylalanine (FF) and glutamic acid (EE) mutants.  
IGF-1R knock-out cells were generated using CRISPR technology. The IGF-1R Double 
Nickase Plasmid (h) (sc-400084-NIC) was obtained from Santa Cruz Biotechnologies, Inc. and 
transfection carried out as described by the supplier protocol. Selection of transfected cells was 
achieved using Puromycin (0.5 µg/ml for MDA-MB-231 and MCF-7 cells and 0.4 µg/ml for 
DU-145 cells). IGF-1R knock-out cell pools were selected by immunoblotting for IGF-1R and 
then cloned by serial dilution. IGF-1R knockout (KO) clones were also subsequently pooled to 
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ensure they represented the original cell cultures. These pools were used for stable transfection 
of pcDNA4 plasmids encoding the WT, FF or EE IGF-1R followed by selection in medium 
supplemented with 400 µg/ml Zeocin over 4 weeks.  
 
SDS -PAGE and western blotting 
Cells were washed with ice-cold PBS twice and lysed immediately with cold lysis buffer (20 
mM Tris, pH 8, 50 mM NaCl, 50mM NaF, 1% NP40) containing protease and phosphatase 
inhibitors for 30 min on ice followed by centrifugation at 14.000 rpm for 15 min at 4˚C. Samples 
were denatured by boiling for 5 min with 5x SDS PAGE loading buffer Technical replicates of 
the same denatured samples (30 µg protein) were separated on 8-10% gels to enable analysis of 
distinct IGF-1R phospho-sites. Proteins were then transferred to nitrocellulose membranes that 
were blocked for 1hr at room temperature in 5% BSA in Tris-buffered saline-T (20 mM Tris, 
150 mM NaCl and 0.05% Tween 20, pH 7.6 (TBS-T). Primary antibodies were diluted at 1/1000 
or 1/10000 dilution for β-actin in TBS-T containing 5% milk or BSA and incubated with 
membranes at 4 °C overnight. To detect distinct IGF-1R phospho-sites each blot was incubated 
with rabbit phospho-IGF-1R or mouse/rabbit total IGF-1R antibodies and a mouse antibody 
detecting a protein input control (tubulin). For detection of p-Thr202/Tyr204/ERK, p-Ser473/AKT 
and p-Tyr239/240 blots were probed with a combination of rabbit antibody detecting the 
phosphorylated protein, a mouse antibody detecting the total protein, followed by mouse 
antibodies to detect the input control. IRDYE-conjugated secondary antibodies (1/10,000) were 
used for detection with the Odyssey Image Scanner System (LI-COR Biosciences). Image studio 
quantification software was used for densitometry. Each phospho-IGF-1R protein was 
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normalized to total IGF-1R, or first to the input control and then to total IGF-1R. Other 
phosphoproteins were normalized to their respective total protein.  
 
Phospho-Tyr1250/1251 antibody adsorption and IGF-1R phosphopetide array 
The phospho-Tyr1250 IGF-1R (Santa Cruz cat#SC-293102, biorbyt cat#orb43345) was adsorbed 
to nitrocellulose membrane that were coated with non-phosphorylated SFYYS peptide. 
Membranes dotted with peptide were allowed to dry completely and blocked with PBS 
containing 1% BSA for 1 hr at RT. These membranes were then incubated with the phospho-
Tyr1250 antibody for 1 hr rotating at RT and the antibody recovered for subsequent use in western 
blotting.   
Custom-made Intavis CelluSpots Peptide arrays (cat #32.100) containing 18 amino acid peptide 
sequences of the IGF-1R and the IR encompassing specific tyrosines and serines phosphorylated 
or non-phosphorylated immobilized on glass arrays were used to analyze the specificity of the 
commercial p-Tyr1250 IGF-1R antibody. The phospho-Tyr1250 antibody (1/500) was incubated 
with slides that were subsequently processed in the same way as western blots.  
 
Immunoprecipitation and in vitro kinase assays 
Cells were lysed and 0.5-1 mg of protein lysate was incubated with antibodies detecting IGF-IR 
(IGF-IRβ Antibody (C-20) cat# sc-713 Santa Cruz, IGF-1Rα Antibody (αIR3) cat#GR11L, 
Merk, IGF-IRβ Antibody cat#3027 Cell Signalling) at 1/100 dilution overnight rotating at 4˚C. 
Immune complexes were obtained by adding 50 µl of pre-washed Protein G-Agarose beads to 
the antibody-lysate mix for 2 hr at 4˚C. Beads were washed three times using lysis buffer and 
loading dye was added to the washed beads (2x) before samples were boiled for 5 mins at 95˚C, 
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centrifuged at 14.000 rpm for 2 min followed by SDS PAGE and western blotting. To investigate 
multiple IGF-1R phospho-sites, denatured samples were split for two sets of gels. The antibody 
detecting the phospho-site was then removed using stripping buffer (200 mM NaOH with 1% 
SDS) and incubated with total IGF-1R (1/1000). 
The ADP-GloTM Kinase Assay kit (Promega) was used for in-vitro kinase assays. For 
kinase assay protein input to immunoprecipitations of IGF-1R WT and FF were adjusted to be 
equivalent to EE.  Beads with immunoprecipitated IGF-1R were washed twice with kinase buffer 
(40 mM Tris (pH 7.5), 20 mM MgCl2, 2 mM MnCl2, 0.1 mg/ml BSA, 2 mM DTT, 100 uM 
Sodium Vanadate) and then incubated with kinase buffer containing 150 µM ATP (ADP-GloTM 
Kinase Assay) and 2 mg/ml poly(Glu, Tyr) (4:1) (P0275; Sigma) as an exogenous substrate for 
30 min, with samples mixed every 10 min. Beads were centrifuged for 30 sec at 14,000 rpm and 
triplicates (5 µl) of supernatant were added to a white 384-well plate for incubation with ADP-
Glo (5 µl per sample) for 60 min at room temperature. The ADP-Glo Kinase detection reagent 
(10 µl) was added to each reaction for 30 min at room temperature, and kinase activity measured 
with a luminometer (BioTek) 
 
Mass spectrometry  
Mass Spectrometry for phospho-peptide mapping of the IGF-1R was carried out at the 
FingerPrints Proteomics Facility the University of Dundee. IGF-1R was immunoprecipitated 
from R- cells transfected with pcDNA3 IGF-1R WT and that were either serum-starved or 
stimulated with IGF-1 were transferred as protein G agarose-bound protein precipitates to the 
Dundee facility where they were subjected to Trypsin/AspN digestion and enrichment of 
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phosphor-peptides by titanium dioxide. Mass Spectrometry was performed using an Orbitrap 
Velos system.  
 
Quantitative PCR  
R- cells transiently expressing WT, FF or EE IGF-1R were prepared for RNA extraction 48 hr 
post-transfection. RNA was extracted using the PureLink RNA Mini Kit (Thermo Scientific) 
according to the manufacturer’s protocol. To synthesize cDNA, 1 µg of RNA and the QuantiTect 
reverse transcription kit (Qiagen) was used. Quantitative PCR was performed using the Roche 
FastStart essential DNA Green Master Kit and the Lightcycler 96 Instrument (Roche 
Diagnostics). Actin was used as housekeeping control. The 2 CT method was used to analyze 
data and to determine relative mRNA expression levels. IGF-1R mRNA expression values were 
normalized to actin and expressed as fold-change relative to the WT IGF-1R (set to 1). The 
following primer set was used to detect IGF-1R: Forward-5' ATGTCCAGGCCAAACAGGAT'3 
and Reverse: 5'CCTCCCACTCATCAGGAACG'3. 
 
Immunofluorescence 
Cells were cultured on 12mm glass coverslips, washed with phosphate-buffered saline, fixed 
with 4% paraformaldehyde in PHEM buffer for 60 min at room temperature, quenched with 50 
mM Ammonium Chloride for 20 min, and permeabilized using 0.1% Triton/PHEM for 5 min. 
PHEM buffer containing donkey serum (10%) was used for blocking and dilution of antibodies. 
Coverslips were incubated with primary antibodies at 4˚C, washed with PHEM 3 times followed 
by secondary antibodies and Hoechst dye to stain nuclei. The following  reagents were used: 
IGF-1 Receptor in mouse cells Cell Signalling  antibody cat# 9750 (1/200), for  human cells cat# 
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3027 (1/200 for MCF-7 cells, 1/100 for other cell lines); the cis Golgi apparatus: GM130 (D 
cat#610822 (1/200): cis- and trans-Golgi network: biotinylated Vicia Villosa (VVA; Lectin 
Vector Laboratories cat#B-1235-2) (1/400). Cy3-conjugated AffiniPure Donkey Anti-Mouse 
antibody (1/1000), Alexa Fluor 488-conjucated AffiniPure Donkey (1/200), Alexa Fluor 594-
conjucated Streptavidin (1/1000) and Alexa Fluor 488-conjucated Streptavidin (1/200) were used 
for detection of primary antibodies. Phalloidin (TRITC Sigma cat# P1951 or AlexaFluor 405 
ThermoFisher cat# A30104) was used to detect Actin, and Hoechst was used to stain nuclei. 
To assess internalization of activated IGF-1R, cells were serum-starved for 4 hr and 
incubated with  the IGF-1R α-chain (IRα) antibody for 30 min either on ice or at 37°C. Cells 
were then fixed and stained with an antibody detecting the IGF-1R β-chain (green). Cells were 
then incubated with secondary antibodies detecting either the IRα (red) or IGF-1R (green). IRα 
antibody bound or internalized with surface-located IGF-1R appeared yellow. 
Images were acquired using a SPOT charge-coupled device camera mounted on a Nikon T600 
fluorescent microscope or a Nikon DSFi1c camera attached to the Leica DM LB2 microscope. 
For confocal microscopy, images were acquired using an Olympus Flouview FV1000 confocal 
laser scanning microscope (numerical aperture: 1.4) with a 60x-immersion objective. Maximum 
intensity projections and z-stacks were processed in Image J. Brightness and contrast were 
adjusted in Adobe Photoshop if needed. To determine fluorescence intensity within the cells, 
ImageJ software was used to determine fluorescence signal intensity within the cells.  
 
In-cell western assays for IGF-1R  
Cells were seeded at 5x104 cells per well in 96-well tissue culture plates in complete medium for 
24 hr, washed three times with PBS, serum-starved for 4 hr followed by stimulation with 10 
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ng/ml IGF-1 for 10 min or left in serum-free medium or complete medium. Cells were 
immediately fixed with 100 µl of a freshly prepared fixing solution (4% formaldehyde/PHEM) 
and incubated at room temperature for 30 min followed by quenching with 50 mM Ammonium 
Chloride for 20 min and washing with PHEM. Cells in wells with complete medium, or 
incubated with p-AKT/AKT and one 3x set of the secondary control antibody were 
permeabilized using 0.1% Triton/PHEM for 5 min and washed with PHEM. All wells were then 
blocked for 1 hr with 50 µl of blocking buffer (5% goat serum/PHEM). Primary antibody (IGF-
1R IR3 for surface and Cell Signaling IGF-1Rβ cat#3027, or p- Ser473/AKT) was added for 2 hr 
with gentle rocking followed by washing and incubation with secondary antibody. Goat anti-
Mouse IRdye® 680 (1/1000) (Odyssey infrared imaging system; cat#926-32220) or Goat anti-
Rabbit IRDye® 800 (1/1000) (Odyssey infrared imaging system; cat#926-32211) were used to 
detect primary antibodies. Syto60 (Invitrogen) was also included (1:10,000) as a cell-permeable 
nucleic acid stain that fluoresces at 680 nm and was detected using the Odyssey infrared scanner. 
Cells were washed five times with PHEM. Plates were dried, and IGF-1R (surface and total 
levels) intensity was quantified using the Image studio quantification software with 
normalization to Syto60 levels. 
 
Cell migration assays  
HS578T cells were seeded in Culture-Insert 2 well 35 mm plates (ibidi Gmbh cat# 81176) 
(4.0x105 cells/ml,70 µl per well). Cells were allowed to attach for 24 hr in serum-free medium 
containing either DMSO (vehicle) or the Golgi disruptor BFA (10 µg/ml) for four hours. The 
wound was generated by removal of the insert and the medium in respective dishes was then 
supplemented with IGF-1 (50 ng/ml). Wounds were photographed with a Nikon charge-coupled 
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device camera connected with the Nikon Eclipse TE 300 microscope (10x magnification) after 0 
hr and 6 hr of migration. For immunofluorescence HS578T cells were seeded in Culture-Insert 2 
well inserts on coverslips (ibidi Gmbh cat# 80209) and allowed to attach for 24 hr. The wound 
area was photographed with a Nikon charge-coupled device camera connected with the Nikon 
Eclipse TE 300 microscope at 0 hr and 6 hr of migration. Subsequently, coverslips were 
recovered for immunofluorescence. 
 
Statistical analysis  
Western blot densitometry results were expressed as fold-change in the ratio of phospho/total 
protein relative to the control condition (set to 1), which is indicated as a white bar in each graph. 
For calculations comparing fold-change of each group to the control, one-sample T-tests were 
used to test the null hypothesis that the expected ratio was 1. For calculations comparing fold 
change of groups (≠ control condition) independent two-sample T-tests were used. P-values were 
adjusted using Benjamini-Hochberg correction for multiple testing. A 3x3 ANOVA was 
conducted to examine the main effects of Group and Condition, and the interaction between 
Group and Condition in Fig 4A. Statistical significance was determined using P-value<0.05 and 
all tests were two-tailed. 
 
Supplementary Materials 
Fig. S1 Immunoreactivity of phosphorylated Tyr1250 IGF-1R antibody 
Fig. S2. Protein abundance and mRNA expression for wild-type and mutant IGF-1Rs stably 
expressed in R- cells 
Fig. S3. WT and EE IGF-1R internalize in large vesicles upon IRα antibody binding 
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Fig. 1. Tyr1250/1251 phosphorylation in cells. (A) Phophopeptides identified by mass 
spectroscopy from IGF-1R immunoprecipitated from R- cells stably expressing WT IGF-1R (R-
/WT cells) following serum starvation or exposure to IGF-1. Phosphorylated (p-) IGF-1R 
tyrosines are indicated in red. (B) Immunoblotting for and quantification of the indicated 
phosphotyrosines (p-Y) in IGF-1R, the indicated phosphorylated forms of AKT and ERK, and 
total IGF-1R, AKT, and ERK from whole lysates of R-/WT cells. Total AKT and ERK, are 
loading controls. Phosphotyrosine-containing proteins were quantified by densitometry, 
normalized to the protein loading control (total AKT, total ERK and IGF-1R) and presented as 
average fold-change ± SEM in the ratio of phosphorylated/total protein relative to the control 
condition (set to 1). (C) Immunoblotting for and quantification of the indicated phosphorylated 
forms of IGF-1R, total IGF-1R, ERK phosphorylated on Tyr202 and Tyr204 (p-T202/Y204), and 
total ERK from R-/WT cells stimulated with IGF-1 at the indicated concentrations and times 
following serum starvation. Quantification of phosphorylated/total IGF-1R is expressed as 
average fold-change ± SEM relative to the control condition (set to 1). Significance was 
calculated using a two-sided one-sample T-test. (D) Immunoblotting for and quantification of 
phosphorylated Tyr1250/1251 in IGF-1R (p-Y1250/1251), total IGF-1R, AKT phosphorylated at 
Ser473, total AKT, ERK phosphorylated at Thr202 and Tyr204, and total ERK from R-/WT cells 
stimulated with IGF-1, IGF-2, or insulin (INS). Densitometry quantification is presented as the 
average fold-change ± SEM in the ratio of phosphorylated/total protein relative to the control 
condition. Significance was calculated using a two-sided one-sample T-test. (E) Immunoblotting 
for IGF-1R phosphorylated on Tyr1135/1136 (p-Y1135/1136), Tyr1250/1251, and total IGF-1R from 
cancer cells serum-starved and stimulated with IGF-1. For all experiments, blots are 
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representative of n≥ 3 independent experiments, and densitometry data was derived from 3 or 
more independent experiments. P-values, *<0.05, **<0.01, ***<0.001. 
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Fig. 2. Adhesion signals and IGF-1R kinase activity promote Tyr1250/1251 phosphorylation. 
(A) Immunoblot of the indicated phosphorylated forms of IGF-1R and total IGF-1R from whole 
 35 
cell lysates of R- cells transiently expressing empty vector (EV) or WT IGF-1R (R-/WT cells) 
that were serum-starved followed by stimulation with IGF-1 for the indicated times. Cells were 
incubated with BMS-754807 for 1 hr prior to IGF-1 stimulation as indicated. Phosphorylated 
Tyr1250/1251 IGF- 1R was quantified by densitometry. (B) Immunoblotting for the total IGF-1R 
and indicated phosphorylated forms of IGF-1R immunoprecipitated from R- cells expressing 
either empty vector, WT IGF-1R or KR mutant IGF-1R that were serum-starved and stimulated 
with IGF-1, or FF mutant cultured in complete medium (CM). AB+B (antibody plus beads) and 
L+B (cell lysate plus beads) are negative controls for immunoprecipitation. Immunoprecipitates 
were incubated with kinase buffer containing ATP or not. IGF- 1R phosphorylated on Tyr1250/1251 
and on Tyr1135/1136   were quantified by densitometry.  Protein input is shown in immunoblots for 
phosphorylated and total IGF-1R, AKT, and ERK. (C) Immunoblotting for and analysis of the 
indicated phosphorylated forms of IGF-1R and Src, total IGF-1R, and total Src from Cal-51 cells 
that were serum-starved, exposed to kinase inhibitors [BMS, BMS-754807 (IGF-1R inhibitor); 
AP-2, AP-26113 (FER inhibitor); PF, PF573228 (FAK inhibitor); PP2 (Src inhibitor)], then 
stimulated with IGF-1. IGF-1R phosphorylated on Tyr1250/1251 IGF- 1R was quantified by 
densitometry. (D) Immunoblotting for the indicated phosphorylated forms of IGF-1R, FAK, 
AKT, and ERK and total IGF-1R, FAK, AKT, and ERK from adherent (ADH) and suspension-
cultured (SUS) R- /WT cells stimulated with IGF-1 for the indicated times following serum 
starvation. The amounts of IGF- 1R phosphorylated on Tyr1250/1251 and on Tyr1135/1136, AKT 
phosphorylated on Ser473, and ERK phosphorylated on Thr202/Tyr204 were quantified by 
densitometry. (E) Immunoblotting for the indicated phosphorylated forms of IGF- 1R, FAK, and 
ERK and total IGF-1R, FAK, and ERK in adherent and suspension-cultured Cal-51 cells serum-
starved and stimulated with IGF-1. For all experiments, densitometric quantification is presented 
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as average fold-change ± SEM in the ratio of phosphorylated/total protein relative to the control 
condition. Significance was calculated using a two-sided one-sample or two-sample T-test. n≥3 
independent experiments. P-values, *<0.05, **<0.01, ***<0.001. 
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Fig. 3. Exogenously expressed Tyr1250/1251 phosphomimetic (EE) IGF-1R is fully active.  
(A) Immunoblot of the indicated phosphorylated forms of  IGF- 1R and total IGF-R1 in R- cells 
and total IGF-1R in IGF-1R knockout (KO) MCF-7, MDA-MB-231, and DU-145 cells 
transiently expressing the WT, FF (Tyr1250/1251 not phosphorylatable), or EE (Tyr1250/1251 
phosphomimetic) forms of IGF-1R. (B) Immunoblotting for the indicated phosphorylated forms 
of IGF-1R, AKT, and ERK and total IGF-1R, AKT, and ERK from R- cells transiently 
overexpressing the WT, FF, or EE form of IGF-1R and stimulated with IGF-1 for the indicated 
times following serum starvation. Significance was calculated using a two-sided two-sample T-
test. (C) Immunoblot of the indicated phosphorylated forms of IGF-1R and AKT and total IGF-
1R and AKT in IGF-1R KO MDA-MB-231 cells transiently overexpressing IGF-1R WT, FF, or 
EE and stimulated with IGF-1 for the indicated times following serum starvation. For (A), (B), 
and (C) densitometry quantification is presented as the average fold-change ± SEM in ratio of 
phosphorylated/total protein relative to the control condition. n≥3 independent experiments. 
Significance was calculated using a two-sided two-sample T-test. (D) Immunoblot of total IGF-
1R from R- cells transiently overexpressing IGF-1R WT, FF, or EE used to determine protein 
input to immunoprecipitate for in vitro kinase assays followed by immunoblotting of 
immunoprecipitated IGF-1R (all adjusted to EE protein amounts). Kinase assay data are 
presented as average fold-change ± SEM in kinase activity (measured in relative luciferase units: 
RLU) relative to control condition (IGF-1R WT). n=3 independent kinase preparations. 
Significance was calculated using two-sided one-sample T-test. P-values, *<0.05, **<0.01, 
***<0.001.  
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Fig. 4. The IGF-1R EE mutant is degraded more rapidly than WT IGF-1R. (A) Immunoblot 
for IGF-1R from R- cells transiently expressing IGF-1R WT, FF, or EE cultured in control 
medium (0 hr) or medium with Cycloheximide (CHX) for 24 hr followed by culture in complete 
medium (chase). Densitometry quantification is presented as the average fold-change ± SEM in 
IGF-1R protein relative to the control condition. n=3 independent experiments. Significance was 
calculated using one-way ANOVA. (B) Immunoblot for total IGF-1R and SNAIL from R- cells 
transiently expressing IGF-1R WT, FF, or EE cultured in control medium (0 hr) or medium 
containing the proteasome inhibitor MG-132. (C) Immunoblots for total IGF-1R and LC3 from 
R- cells transiently expressing IGF-1R WT, FF, or EE cultured in control medium (0 hr), or 
medium containing the lysosome inhibitors Leupeptin and E64D (Leu+E64D) or Chloroquine 
(CQ). (D) Immunoblots for IGF-1R from R- cells transiently expressing IGF-1R WT, FF, or EE 
stimulated with the indicated concentrations of IGF-1 for the indicated times. For (B), (C), (D) 
densitometry quantification is presented as average fold-change ± SEM in IGF-1R protein 
relative to control condition. n=3 independent experiments. Significance was calculated using a 
two-sided one-sample or two-sample T-test. P-values, *<0.05, **<0.01, ***<0.001. 
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Fig. 5. Tyr1250/1251 phosphorylation promotes IGF-1R translocation to Golgi. 
(A) Immunofluorescence of R- cells transiently expressing the IGF-1R WT, FF, or EE mutant 
showing IGF-1R (green) and nuclei (blue) following serum starvation (0 min) or IGF-1 
stimulation (5 and 10 min). Images are representative of n≥4 experiments. (B) IGF-1R staining 
intensity (green) in relation to the nuclear area (blue) measured using the RGB profiler from 
Image J software along a line drawn through the cell passing through the nucleus. (C) Results of 
in-cell-western from R- cells transiently transfected with WT, FF, or EE IGF-1R probed for total 
(TR) and surface (SR) IGF-1R. Densitometry quantification is presented as average 
fold- change ± SEM in IGF-1R surface protein relative to the control condition. n=3 independent 
experiments. Significance was calculated using a two-sided one-sample or two-sample T-test. 
(D) Confocal microscopy showing R- cells transiently expressing the WT, FF, or EE IGF-1R that 
were serum-starved for 4 hr or incubated with an antibody binding to the IGF-1R α-chain (IRα). 
Co-localization of IGF-1R IRα antibody [detected with secondary (2°) antibody, in red] and IGF-
1Rβ (green) is indicated as a yellow signal. Images are representative of n=2 independent 
experiments, each with n≥3 cells. P-values, *<0.05, **<0.01, ***<0.001. Scale bars, 50 µm. 
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Fig. 6. Tyr1250/1251 phosphorylation promotes IGF-1R translocation to the Golgi apparatus. 
(A) Immunofluorescence of R- cells expressing WT, FF, or EE IGF-1R that were either serum-
starved (0 min) or stimulated with IGF-1 (5, 10, 30 min) showing IGF-1R (green), the cis-Golgi 
marker GM130 (red), and nuclei (blue). Scale bar, 50 µm. Images are representatives of n≥3 
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independent experiments. (B) Immunofluorescence of R- cells expressing WT, FF, or EE IGF-
1R following IGF-1 stimulation for the indicated times showing IGF-1R (green), the Golgi 
marker VVA (red or green) or GM130 (red), and nuclei (blue). Representative images of n=2 
independent experiments, with n≥3 images acquired for each experiment, are shown. Scale bar, 
50 µm scale bar (IGF-1R, VVA) and 20 µm (VVA/GM130). (C) Immunoblot for total IGF-1R 
from R- cells transiently expressing WT, FF, or EE IGF-1R cultured in control medium (0 hr) or 
medium containing the Golgi disruptor Brefeldin A (BFA). Densitometry quantification is 
presented as average fold- change ± SEM in IGF-1R protein relative to the control condition. 
n=3 independent experiments. Significance was calculated using a two-sided one-sample or two-
sample T-test. P-values, *<0.05, **<0.01, ***<0.001. 
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Fig. 7. Tyr1250/1251 is phosphorylated in Golgi-localized IGF-1R in migratory cancer cells. 
(A) Immunofluorescence of MCF-7, MDA-MB-231, and HS578T cells stained to show IGF-1R 
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(green) and either the cis-Golgi marker GM130 or the cis/trans-Golgi marker VVA (red). Images 
are representative of n≥3 independent experiments. (B) Immunoblot for IGF-1R from MCF-7, 
MDA-MB-231, and HS-578T cells cultured in control medium (0 hr) or medium containing the 
Golgi disruptor Brefeldin A (BFA) for 4 hr. Densitometry quantification is presented as average 
fold-change ± SEM in IGF-1R protein relative to the control condition. n≥3 independent 
experiments. Significance was calculated using a two-sided one-sample T-test. 
(C) Immunofluorescence of MCF-7, MDA-MB-231, and HS-578T cells cultured in control 
medium (0 hr) or medium containing Brefeldin A (BFA) for 4 hr and stained for IGF-1R (green) 
and either GM130 or VVA (red). Images are representatives of n≥3 independent experiments. 
(D) Immunoblot of the indicated phosphorylated forms of  IGF- 1R, SHC, and AKT and total 
IGR-1R, AKT, and SHC in lysates from MCF-7 and HS-578T cells stimulated with IGF-1 for 
the indicated time following 4 hr serum starvation in the presence or absence (Ctl) of BFA. 
Densitometry quantification is presented as the average fold-change ± SEM in ratio of 
phosphorylated/total protein relative to the control condition. n≥3 independent experiments. 
Significance was calculated using a two-sided one-sample or two-sample T-test. P-values, 
*<0.05, **<0.01, ***<0.001. All scale bars, 20 µm.    
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Fig. 8. Tyr1250/1251 phosphorylation correlates with IGF-1R presence in the Golgi in 
migrating cancer cells. (A) Immunofluorescence of MCF-7 and HS-578T cells stained for IGF-
1R (green), the cis-Golgi marker GM-130 (red), and actin (blue) at the indicated times after 
being cultured on Fibronectin-coated coverslips. Images are representative of n≥3 independent 
experiments. (B) Immunoblotting for the indicated phosphorylated forms of IGF- 1R, FAK, 
AKT, and ERK and total IGF-1R, FAK, AKT, and ERK from MCF-7 and HS-578T cells 
cultured on fibronectin-coated plates for the indicated times. Densitometry quantification is 
presented as the average fold-change ± SEM in ratio of phosphorylated/total IGF-1R relative to 
the control condition over time. n≥3 independent experiments. Significance was calculated using 
a two-sided one-sample T-test. (C) Phase-contrast images of HS-578T cells in a scratch wound 
assay at the indicated time points, and these cells fixed and stained for IGF-1R (green), GM-130 
(red), and actin (blue). Images are representative of n=3 independent experiments. (D) Phase 
contrast images of HS-578T cells in a wounding assay in serum-free control medium (no IGF-1) 
or in the presence of IGF-1, with vehicle or BFA added at 0 and 6 hr after wounding. Images are 
representative of n=3 independent experiments. (E) Immunofluorescence of sub-confluent and 
confluent MCF-7 and HS-578T cells stained for IGF-1R (green) and either GM130 or actin 
(red). Images are representative of n=3 independent experiments. (F) Immunoblotting for the 
indicated phosphorylated forms of IGF-1R, FAK, SHC, AKT, and ERK and total IGF-1R, FAK, 
SHC, AKT, and ERK from sub-confluent (SUB) and confluent (CON) MCF-7 and HS-578T 
cells stimulated with IGF-1 following serum starvation. Densitometry quantification is presented 
as the average fold-change ± SEM in ratio of phosphorylated/total protein relative to the control 
condition. n=3 independent experiments. Significance was calculated using a two-sided one-
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sample or two sample T-test. P-values, *<0.05, **<0.01, ***<0.001. Scale bars, 250 µm (phase) 
and 20 µm (fluorescence).  
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Fig. 9. Model for function of Tyr1250/1251 phosphorylation in determining IGF-1R location 
and signaling in the Golgi apparatus. IGF-1 and adhesion signals promote the phosphorylation 
of IGF-1R at Tyr1250/1251 in both non-migratory and migratory cells. In non-migratory cells, the 
IGF-1R is predominantly located at the plasma membrane or at stable focal adhesion points. In 
migratory cells, the IGF-1R is predominantly located in the Golgi apparatus. Upon induction of 
cell migration, IGF-1R translocates from the Golgi to the leading edge of the cell, subsequently 
becomes phosphorylated, and returns to the Golgi, where it mediates signaling to downstream 
effectors, including SHC and ERK. 
